https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-10 08:39:572025-01-10 08:39:57David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-10 08:39:572025-01-10 08:39:57David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-09 13:18:292025-01-09 13:18:29Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-09 13:13:182025-01-09 13:13:18Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
https://www.optimumcomms.com/wp-content/uploads/2023/07/Template_Logo_300x180px-80x80Web_Logos-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-09 08:49:112025-01-09 08:49:11Astraveus opens path to accessible cell therapies with first ever end-to-end microfluidic CAR-T production
https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-09 08:45:022025-01-10 12:21:50Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-08 08:35:452025-01-08 08:35:45Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2024/12/Antag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-08 08:33:272025-01-08 08:33:27Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-07 08:49:132025-01-07 08:49:134SC announces update relating to Resminostat’s (Kinselby) Marketing Authorisation Application
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-07 08:44:032025-01-07 12:37:07Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-07 08:35:062025-01-07 08:35:06Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-07 08:33:132025-01-07 16:38:40Vesper Bio initiates Phase Ib/IIa proof of concept study of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia (FTD)
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-06 11:57:082025-01-06 11:57:53Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-01-02 09:01:172025-01-02 11:51:43Combination of Poolbeg and HOOKIPA Pharma Inc.
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-23 11:53:432024-12-23 11:53:43European Energy and Novo Holdings announce joint venture to triple renewable energy capacity of German onshore wind parks
https://www.optimumcomms.com/wp-content/uploads/2023/06/Sequana_Medical_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-23 08:38:092024-12-23 08:38:09Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
https://www.optimumcomms.com/wp-content/uploads/2024/12/Targed-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-19 08:51:062024-12-19 08:58:07TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTPWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
